Clinical trials: Locally Advanced Cervical Squamous Cell Carcinoma
Locally Advanced or Metastatic Solid Tumors
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
This is an early development study of ASP388B in people with solid tumors. In this study, ASP388B will be given to people for the first time. It will be given by itself or together with standard cancer therapies.
- Trial name
- NCT07730021
- Testing
- ASP388B, Pembrolizumab, Carboplatin
- Where
- 4 sites in United States, Japan
- Volunteers
- 392 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Carcinoma, Squamous Cell of Head and Neck
Phase III Trial of PET/CT vs. CTSurveilance for Head and Neck Cancer
The null hypothesis is that patients screened by PET/CT will not have detection of disease recurrence any earlier than those screened by CT alone.
- Trial name
- NCT02655068
- Testing
- PET/CT, Computed Tomography (CT)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Pittsburgh
Esophageal Cancer
Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer
We intend to conduct a prospective single-arm clinical study to explore the efficacy and safety of immunochemotherapy in neoadjuvant therapy in elderly patients with advanced esophageal squamous cell carcinoma.
- Trial name
- NCT06403878
- Testing
- Carboplatin, Nab paclitaxel, Sintilimab
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Sichuan University
Esophageal Squamous Cell Carcinoma
Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
To investigate the safety and activity of preoperative pembrolizumab combined with chemoradiotherapy for resectable esophageal squamous cell carcinoma (ESCC) ,20 patients enrolled in Phase Ib PALACE-1(NCT03792347).The results…
- Trial name
- PALACE-2 (NCT04435197)
- Testing
- Pembrolizumab Injection
- Where
- 2 sites in China
- Volunteers
- 143 people
- Sponsor
- Ruijin Hospital
Esophageal Squamous Cell Carcinoma
A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC
The purpose of this study is to observe and evaluate the efficacy and safety of Sintilimab for Consolidation Therapy After Radical Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04514835
- Testing
- Cisplatin+Capecitabine+Sintilimab
- Where
- China
- Volunteers
- 44 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Squamous Cell Carcinoma of the Head and Neck
Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer
This study has two, independent, cohorts, both in locally advanced squamous cell head and neck cancer. The purpose of the first cohort is to determine whether nivolumab in combination with radiotherapy is more effective than…
- Trial name
- NCT03349710
- Testing
- Nivolumab, Cetuximab, Cisplatin
- Where
- 55 sites in United States, France and 8 more
- Volunteers
- 74 people
- Sponsor
- Bristol-Myers Squibb
Head and Neck Cancer, Squamous Cell Carcinoma
Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer
The addition of chemotherapy to radiotherapy (chemoradiation) has improved outcomes for patients with locally advanced squamous cell carcinoma of the head and neck but additional improvements to treatment regimens are needed.
- Trial name
- NCT00500760
- Testing
- Cisplatin, Standard Fractionation Radiotherapy, Panitumumab
- Volunteers
- 153 people
- Sponsor
- Amgen
Head and Neck Cancer
A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer
The purpose of this study is to determine the effectiveness and side effects of a new combination and schedule of chemotherapy drugs in the treatment of head and neck cancer.
- Trial name
- NCT00148122
- Testing
- Docetaxel, Capecitabine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan Rogel Cancer Center
Squamous Cell Carcinoma
Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer
This study utilizes two cycles of Paclitaxel and Carboplatin chemotherapies followed by four small doses of radiation, prior to other treatment (surgery or radiation).
- Trial name
- NCT00176254
- Testing
- Radiotherapy, Paclitaxel, Carboplatin
- Volunteers
- 40 people
- Sponsor
- Susanne Arnold
Esophageal Squamous Cell Carcinoma
Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma
This study aims to evaluate the efficacy and safety of neoadjuvant sacituzumab tirumotecan (SKB264/MK-2870) combined with toripalimab in patients with locally advanced, resectable esophageal squamous cell carcinoma (ESCC).
- Trial name
- NCT07823270
- Testing
- Sacituzumab tirumotecan, Toripalimab
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Hebei Medical University Fourth Hospital
Head and Neck Cancer
Cisplatin or Carboplatin Combined With Gemcitabine in Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor
RATIONALE: Drugs used in chemotherapy, such as cisplatin, carboplatin, and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00079079
- Testing
- carboplatin, cisplatin, gemcitabine hydrochloride
- Where
- 4 sites in Canada
- Volunteers
- 34 people
- Sponsor
- NCIC Clinical Trials Group
Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma
Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer
This phase II trial studies how well docetaxel, cisplatin and fluorouracil work in treating patients with previously untreated stage II-IV nasal cavity and/or paranasal sinus cancer.
- Conditions
- Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma, Sinonasal Undifferentiated Carcinoma, Stage II Nasal Cavity and Paranasal Sinus Cancer AJCC v8
- Trial name
- NCT00707473
- Testing
- Carboplatin, Chemoradiotherapy, Cisplatin
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Carcinoma
Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
To evaluate the efficacy and safety of neoadjuvant therapy of camrelizumab combined with chemotherapy for resectable locally advanced esophageal squamous cell carcinoma
- Trial name
- NCT05476380
- Testing
- camrelizumab
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Neoplasms, Head and Neck
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)
- Trial name
- JADE (NCT06256588)
- Testing
- Dostarlimab
- Where
- 277 sites in United States, Argentina and 29 more
- Volunteers
- 864 people
- Sponsor
- GlaxoSmithKline
Squamous Cell Carcinoma of Head and Neck
A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer
This is a single arm phase II trial to study the efficacy and safety of a Cdk inhibitor P276-00 in the treatment of squamous cell carcinoma of head and neck.
- Trial name
- MONARCH (NCT00824343)
- Testing
- P276-00
- Where
- 9 sites in India
- Volunteers
- 86 people
- Sponsor
- Piramal Enterprises Limited